![]() She investigates immunotherapy for hepatocellular cancer and melanoma, involving peptides, dendritic cells and adenoviruses as well as effector responses to tumor antigens. Her research focuses on the development of advanced cellular therapies and cancer vaccines. Butterfield is the Vice President of Research and Development at the Parker Institute for Cancer Immunotherapy and an Adjunct Professor of Microbiology and Immunology at the University of California, San Francisco. ![]() “RAPT’s comprehensive approach to clinical development employing biomarkers to identify patients most likely to respond to therapy offers hope for even the most devastating cancers.”ĭr. “It’s a very exciting time in the field of immuno-oncology, with deeper knowledge of biological functions elucidating new ways to treat disease effectively,” commented Dr. and Lawrence Fong, M.D., to its Scientific Advisory Board. ![]() ![]() (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the addition of preeminent oncology thought leaders, Lisa Butterfield, Ph.D. 14, 2020 (GLOBE NEWSWIRE) - RAPT Therapeutics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |